AtriCure Inc. (ATRC)
NASDAQ: ATRCHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ATRC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.71B
- P/E (TTM)
- 253.86
- Forward P/E
- 122.84
- EPS (TTM)
- $0.21
- Dividend yield
- None
- 52-week range
- 25.36 – 61.70
- Day range
- 52.98 – 54.88
- Volume / Avg
- 753.53K / 1.09M
- Beta
- —
- Shares outstanding
- 50.87M
- Next earnings
- Nov 4, 2026
52-week range
ATRC stock today
AtriCure (ATRC) closed at $53.31 on Oct 7, down 0.69% (-$0.37), versus the S&P 500's 0.22% decline. At this level, ATRC sits in the middle of its 52-week range of $25.36 to $61.70: 13.6% below the high, set on Sep 24, 2026 and 110.2% above the low. ATRC is up 34.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 56.2%.
At 253.9x trailing earnings, AtriCure trades above the peer-group median of 29.7x. Its forward P/E of 122.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. AtriCure's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About AtriCure
Company profileAtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Michael H. Carrel
- Headquarters
- Mason, OH
- Employees
- 1,350
- IPO year
- 2005
- Website
- atricure.com
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$54.89+2.96%
- Strong buy 3
- Buy 4
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.01
ATRC news
All ATRC newsAtriCure peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| UFPTUFP Technologies Inc. | 292.87 | -3.30% | $2.27B | vs ATRC |
| IRTCiRhythm Holdings Inc. | 104.99 | -2.06% | $3.46B | vs ATRC |
| PLSEPulse Biosciences Inc | 49.09 | -1.33% | $3.50B | vs ATRC |
| INSPInspire Medical Systems Inc. | 67.45 | -1.10% | $1.95B | vs ATRC |
| LMATLeMaitre Vascular Inc. | 79.31 | +0.33% | $1.81B | vs ATRC |
| NVSTEnvista Holdings Corporation | 23.04 | -0.99% | $3.70B | vs ATRC |
| NVCRNovoCure Limited | 14.66 | -2.07% | $1.71B | vs ATRC |
| XRAYDENTSPLY SIRONA Inc. | 8.54 | +0.23% | $1.70B | vs ATRC |
Indexes, lists and sector
AtriCure stock FAQ
What is AtriCure's stock price today?
ATRC last traded at $53.31 as of Oct 7, 4:00 PM EDT, down 0.69% on the day. Prices are delayed at least 15 minutes.
When is AtriCure's next earnings date?
AtriCure is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.01.
What is ATRC's P/E ratio?
ATRC trades at a trailing P/E ratio of 253.86 and a forward P/E of 122.84, compared with a median of 29.7 for its closest peers.
Who is AtriCure's CEO?
Mr. Michael H. Carrel is the chief executive officer of AtriCure Inc., which has about 1,350 employees.
What is the ATRC 52-week high?
The 52-week high for ATRC is $61.70 and the 52-week low is $25.36. The stock is currently 13.6% below its high.